Dr. Apurba K Bhattacharjee, Georgetown University Medical Center, Georgetown University(More Info)
Pharmacophore modeling for potential drug discovery – October 14th, 2020
View recording
Q&A
Dr. Evan Feinberg, Genesis Therapeutics(More Info)
Unifying AI and biotech to accelerate and optimize drug discovery & development – November 11th, 2020
Dr. Zachary Sun, Tierra Biosciences(More Info)
Cell-free synthetic biology for high-throughput, custom protein production -December 16th, 2020
Dr. Ana Cristina Puhl Rubio, Collaborations Pharmaceuticals(More Info)
COVID-19 Drug Discovery at Collaborations Pharmaceuticals – March 3rd, 2021
View recording
Q&A
Dr. Kaushik Chakravarty, VeriSIM Life(More Info)
Redefining preclinical and clinical drug development to advance human health – March 31st, 2021
|
Dr. Spandan Chennamadhavuni, Emory University(More Info)
Novel Macrocyclic Drugs for cancer Treatment – Exploring “beyond rule-of-five (bRo5)” chemical space – October 21st, 2020
View recording
Q&A
Dr. Justin Hall, Pfizer Pharmaceuticals(More Info)
A simple model for determining ligand affinity from irreversible thermal shifts – October 28st, 2020
View recording
Dr. Lewis D. Pennington, Alkermes(More Info)
Leveraging the Necessary Nitrogen Atom for Multiparameter Optimization in Chemical Biology and Drug Discovery – Nov 18th, 2020
View recording
Q&A
Dr. Surya K. De, Supra Sciences(More Info)
Drug Discovery Hit to Lead – Inhibitors of PI-3K/AKT/mTOR Pathway – January 13th, 2021
View recording
Dr. Vincent Jacques, DeuteRx, LLC(More Info)
Deuterium in drug discovery and development – February 10th, 2021
View recording
Dr. Apurba Dutta, University of Kansas(More Info)
Cytotoxic Marine Natural Product Jaspine B: A Medicinal Chemical Investigation – April 14th, 2021
View recording
Dr. Nicholas A. Meanwell, Bristol Myers Squibb(More Info)
The Discovery of the HIV-1 Attachment Inhibitor Fostemsavir – April 28th, 2021
Dr. Bing Xia, GlaxoSmithKline(More Info)
DEL-Enabled Discovery of Novel MoA and Structurally Unique IDO1 Inhibitors – April 21st
Dr. Ian Storer, AstraZeneca(More Info)
Fragment screening as an adaptable approach for hit-to-lead generation in medicinal chemistry – May 5th, 2021
|
Dr. Lore Gruenbaum, The Leukemia & Lymphoma Society (More Info)
Antibody and Cell Therapies in blood cancer: successes & challenges – December 2nd, 2020
View recording
Dr. Haizhen Liu, BioAtla(More Info)
Novel Conditional Active Bispecific T Cell Engagers Targeting Solid Tumors – January 20th, 2021
Dr. Uriel Moreno, Stanford University(More Info)
Plasticity of Human Natural Killer Cells in the Tumor Microenvironment -March 17th, 2021
View recording
Dr. Jeffrey Leyton, Université de Sherbrooke (More Info)
Journey to the Center of the Cell: Reprogramming Intracellular Transport to the Nucleus Enhances Tumor Killing for Antibodies Conjugated to Nuclear-Active Payloads – February 24th, 2021
View recording
|
Dr. Yurong Lai , Gilead Sciences(More Info)
Model informed compound selection in drug discovery: The Why and How – November 4th, 2020
View recording
Q&A
Dr. Kin-Hoe Chow, Dana Farber Institute(More Info)
Creation of patient derived cancer models at scale leverages patient diversity for improved clinical trials predictions – December 9th, 2020
|